Tag:
NVA237
Latest Headlines
Latest Headlines
Novartis signals serious U.S. delay for blockbuster COPD program
Novartis's blockbuster plans to develop a game-changing combo COPD therapy for the U.S. market have run into a serious delay. The pharma giant noted today that investigators will need to come up with
Novartis preps European COPD drug app for NVA237
Investigators for Novartis said that two studies for their smoker's cough drug--NVA237--turned in promising data for improving patients' ability to breathe, setting the stage for a regulatory filing
Novartis unveils more promising Ph3 data on COPD program
Novartis continues to rack up an impressive set of late-stage data on NVA237, an experimental COPD treatment that is considered a likely winner at the FDA. The data demonstrated the treatment was
Novartis' Ph3 success advances blockbuster COPD program
On a day that Novartis ($NVS) is earning kudos for its ability to gain new drug approvals, the pharma company is reporting fresh progress with its closely-watched COPD program. A Phase III study of
